Management of retinopathy of prematurity

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 98, Issue 5, 2013, Pages

  Fleck, Brian William ^a  

^a Princess Alexandra Eye Pavilion ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; SOMATOMEDIN C; VASCULOTROPIN;

ANGIOGENESIS; BLINDNESS; BODY DISTRIBUTION; CLINICAL PRACTICE; DIODE LASER; GESTATIONAL AGE; HUMAN; INSULIN INFUSION; INSULIN TREATMENT; LASER SURGERY; LOW LEVEL LASER THERAPY; META ANALYSIS; MONOTHERAPY; MUELLER CELL; OXYGEN SATURATION; OXYGEN THERAPY; PERINATAL PERIOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA BLOOD VESSEL; RETINA MACULA AGE RELATED DEGENERATION; RETROLENTAL FIBROPLASIA; REVIEW; THERAPY EFFECT; WEIGHT GAIN;

BEVACIZUMAB; NEONATOLOGY; OPHTHALMOLOGY; OXYGEN; RETINOPATHY OF PREMATURITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INFANT, NEWBORN; INTRAVITREAL INJECTIONS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84883469308     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303933     Document Type: Review

References (33)

1. Wilkinson AR, Haines L, Head K, et al. UK retinopathy of prematurity guideline. Eye 2009;23:2137-9.
2. Section on Ophthalmology American Academy of Pediatrics, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2006;117:572-6.
3. Vaucher YE, Peralta-Carcelen M, Finer NN, et al. Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med 2012;367:2495-504.
4. Mintz-Hittner HA, Kennedy KA, Chuang AZ, et al. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
5. Gilbert C. Retinopathy of prematurity: a global perspective of the epidemics, population of babies at risk and implications for control. Early Hum Dev 2008;84:77-82.
6. Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003;121:1684-94.
7. Fleck BW, McIntosh N. Pathogenesis of retinopathy of prematurity and possible preventive strategies. Early Hum Dev 2008;84:83-8.
8. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that 'physiological hypoxia ' is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995;36:1201-14.
9. Hellstrom A, Engstrom E, Hard AL, et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003;112:1016-20. (Pubitemid 37339551)
10. Hellstrom A, Perruzzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001;98:5804-8. (Pubitemid 32435723)
11. Austeng D, Kallen KB, Hellstrom A, et al. Natural history of retinopathy of prematurity in infants born before 27 weeks' gestation in Sweden. Arch Ophthalmol 2010;128:1289-94.
12. Sato T, Kusaka S, Shimojo H, et al. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology 2009;116:1599-603.
13. International Committee for the Classification of Retinopathy of Prematurity. The international classi fication of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-9.
14. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000;105:295-310.
15. Kinsey VE. Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 1956;56:481-543.
16. Cross KW. Cost of preventing retrolental fibroplasia? Lancet 1973;2:954-6.
17. Askie LM, Brocklehurst P, Darlow BA, et al. NeOProM: Neonatal Oxygenation Prospective Meta-analysis Collaboration study protocol. BMC Pediatr 2011;11:6.
18. Stenson B, Brocklehurst P, Tarnow-Mordi W, et al. Increased 36-week survival with high oxygen saturation target in extremely preterm infants. N Engl J Med 2011;364:1680-2.
19. Lofqvist C, Andersson E, Sigurdsson J, et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006;124:1711-18. (Pubitemid 44913194)
20. Can E, Bulbul A, Uslu S, et al. Effects of aggressive parenteral nutrition on growth and clinical outcome in preterm infants. Pediatr Int 2012.
21. Beardsall K, Ogilvy-Stuart AL, Frystyk J, et al. Early elective insulin therapy can reduce hyperglycemia and increase insulin-like growth factor-I levels in very low birth weight infants. J Pediatr 2007;151:611-17, 7 e1.
22. Ley D, Hansen-Pupp I, Niklasson A, et al. Longitudinal infusion of a complex of insulin-like growth factor-I and IGF-binding protein-3 in five preterm infants: pharmacokinetics and short-term safety. Pediatr Res 2013;73:68-74.
23. Lofqvist C, Niklasson A, Engstrom E, et al. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res 2009;65:574-9.
24. Connor KM, SanGiovanni JP, Lofqvist C, et al. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med 2007;13:868-73. (Pubitemid 47038185)
25. Dhaliwal CA, Wade J, Gillespie T, et al. Early retinal blood vessel growth in normal and growth restricted rat pups raised in oxygen and room air. Br J Ophthalmol 2011;95:1592-6.
26. Hu J, Blair MP, Shapiro MJ, et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012;130:1000-6.
27. Castellanos MA, Schwartz S, Garcia-Aguirre G, et al. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity. Br J Ophthalmol 2013;97:816-19.
28. Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol 2012;22:685-6.
29. Stewart MW. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflamm Allergy Drug Targets 2011;10:497-508.
30. Investigators IS, Chakravarthy U, Harding SP, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119:1399 -411.
31. Sato T, Wada K, Arahori H, et al . Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 2012;153:327-33 e1.
32. Hoerster R, Muether P, Dahlke C, et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol 2013;91:e74-5.
33. Fledelius HC, Fledelius C. Eye size in threshold retinopathy of prematurity, based on a danish preterm infant series: early axial eye growth, pre- and postnatal aspects. Invest Ophthalmol Vis Sci 2012;53:4177-84.